Central Institute of Mental Health, Mannheim

The Central Institute of Mental Health (ZI Mannheim) is a leading German psychiatric research institute affiliated with Heidelberg University, and under Prof. Dr. Gerhard Gründer is one of Europe’s foremost centers for psychedelic research—co-leading EPIsoDE, Germany’s first federal government-funded (BMBF, €2.2M) Phase II RCT of psilocybin for treatment-resistant depression, and receiving one of the first compassionate-use approvals for psilocybin in Germany and the EU, with results published in Lancet Psychiatry in 2025. The institute also conducts molecular neuroimaging research on MDMA and psilocybin mechanisms, and has reported successful ketamine treatment outcomes in treatment-resistant depression.